Saturday 17 October 2026 Export GKOS’s income statement to Excel — free account

Glaukos Corporation

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024. In the quarter to June 2026, revenue grew 49.5%, EPS grew 8.82%, free cash flow grew 211.8% and total debt fell 2.15%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

164.84 0.76 −0.46%

Follow GKOS

Alert me

Market cap: $9.8B
P/E: 0.0×
Fwd P/E: −139×
Dividend yield: —
F-score: 3/9
Altman Z: 15.20
Beneish M: −2.96
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 69.31

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	1	4	1	4	2	4	1	5	4	2	1

Insider Ownership 3.70%

Capital & Financial Ratios $m

Market Cap 9,770.00

Revenue 612.84

Net Income (188.05)

Free Cash Flow (12.20)

Net Debt (218.88)

Current Ratio 5.04

Debt/Equity 0.10

P/E ratio 0.00

Fwd P/E (139.00)

P/S ratio 15.82

P/B ratio 14.21

Past 5Y EPS Growth —

This Y EPS Growth 65.84%

Next Y EPS Growth 270.69%

Next Y revenue growth 36.31%

Next 5Y EPS Growth 51.45%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 87.91%

10-year low 10-year high

P/B against its own 10 years 94.66%

10-year low 10-year high

EV/Sales against its own 10 years 87.95%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	295	319	279	286
Receivables	40	61	109	139
Inventory	42	58	64	59
Other	—	—	—	—
	395	450	475	516

	2023	2024	2025	Q'26
Payables	13	13	25	19
ST’ Debt	—	—	—	—
Other	—	—	—	—
	74	75	101	102

Compound Annual Growth %

	10y	5y	3y
Sales	21.61%	17.67%	21.51%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	21.29%	(0.34%)	7.38%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	151	186	—	—	—
’25	107	124	134	143	507
’24	86	96	97	105	383
’23	74	80	78	82	315
’22	68	73	71	71	283
’21	68	78	75	73	294
’20	55	32	65	73	225

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	15	—	—	—
’25	(19)	7	(10)	7	(15)
’24	(34)	(18)	(10)	1	(61)
’23	(31)	(8)	(8)	(11)	(58)
’22	10	(12)	(27)	(4)	(33)
’21	4	7	18	(5)	25
’20	(13)	(11)	(10)	11	(23)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(16)	12	—	—	—
’25	(20)	(11)	(12)	4	(39)
’24	(35)	(20)	(11)	(1)	(68)
’23	(38)	(14)	(12)	(15)	(78)
’22	3	(22)	(33)	(12)	(63)
’21	(13)	(4)	8	(14)	(23)
’20	(14)	(14)	(11)	8	(30)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.34)	(0.31)	—	—	—
’25	(0.32)	(0.34)	(0.28)	(2.32)	(3.28)
’24	(0.82)	(1.06)	(0.39)	(0.60)	(2.77)
’23	(0.72)	(0.68)	(0.63)	(0.75)	(2.78)
’22	0.11	(0.96)	(0.58)	(0.66)	(2.09)
’21	(0.36)	(0.38)	0.13	(0.47)	(1.07)
’20	(1.24)	(0.90)	(0.35)	(0.24)	(2.70)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	14.25	23.08	25.25	50.60	23.31	39.35	33.33	42.48	74.75	73.16	Analyst estimates 2026–2028 Powerpack
	High	39.82	52.49	70.91	84.65	76.20	99.00	64.49	86.53	153.50	163.71
People
People	Employees	264	387	437	600	653	727	783	907	995	1,094
	Revenue/emp, $m	0.43	0.41	0.41	0.39	0.34	0.40	0.36	0.35	0.39	0.46
Income, $m
Income, $m	Revenue	114	159	181	237	225	294	283	315	383	507
	Gross margin, %	85.86	86.78	86.17	83.72	59.23	77.34	75.61	75.99	75.48	77.97
	EBT	5	0	(12)	(50)	(132)	(49)	(98)	(134)	(146)	(193)
	EBT margin, %	3.99	0.00	(6.82)	(21.11)	(58.82)	(16.76)	(34.80)	(42.49)	(37.97)	(38.04)
	Net income	5	0	(13)	15	(120)	(50)	(99)	(135)	(146)	(188)
	Depreciation	5	6	6	14	66	37	38	38	37	39
Per share, $
Per share, $	Revenue	3.47	4.63	5.13	6.34	5.06	6.33	5.96	6.50	7.27	8.87
	Earnings	0.14	0.00	(0.37)	0.41	(2.70)	(1.07)	(2.09)	(2.78)	(2.77)	(3.28)
	Cash flow	0.37	0.76	0.53	(0.01)	(0.52)	0.53	(0.70)	(1.19)	(1.16)	(0.26)
	Capex	(0.19)	(0.18)	(0.29)	(0.13)	(0.16)	(1.03)	(0.63)	(0.42)	(0.12)	(0.42)
	Free cash flow	0.18	0.58	0.24	(0.14)	(0.67)	(0.50)	(1.33)	(1.61)	(1.28)	(0.68)
	Book value	3.56	4.02	4.92	18.02	15.00	12.65	11.17	9.53	14.54	11.47
	Shares, m	33	34	35	37	44	46	47	48	53	57
Valuation, ×
Valuation, ×	P/E	253.15	0.00	0.00	160.21	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	9.71	5.85	10.94	8.59	14.89	7.02	7.36	11.86	20.63	12.73
	P/B	9.47	6.74	11.41	3.02	5.02	3.51	3.93	8.08	10.31	9.84
	EV/Sales	8.90	5.12	10.19	8.11	14.21	7.76	8.35	12.93	20.71	12.86
	EV/FCF	168.84	41.25	216.06	(377.22)	(106.79)	(98.86)	(37.38)	(52.18)	(117.49)	(167.07)
Cash, $m
Cash, $m	Operating cash flow	12	26	19	0	(23)	25	(33)	(58)	(61)	(15)
	Capex	(6)	(6)	(10)	(5)	(7)	(48)	(30)	(20)	(6)	(24)
	Free cash flow	6	20	9	(5)	(30)	(23)	(63)	(78)	(68)	(39)
Balance, $m
Balance, $m	Working capital	103	123	146	205	420	423	372	321	375	374
	Total debt	—	—	—	58	250	353	354	353	69	68
	Net debt	(96)	(119)	(140)	(116)	(154)	(61)	1	58	(249)	(211)
	Shareholders’ equity	117	138	174	673	667	587	530	462	767	656
Returns, %
Returns, %	ROA	3.60	(0.06)	(6.95)	3.01	(13.20)	(4.83)	(9.67)	(13.86)	(15.29)	(20.09)
	ROIC	12.37	(7.43)	(24.35)	(5.64)	(15.05)	(3.91)	(9.69)	(15.48)	(14.78)	(28.00)
	ROE	4.26	(0.07)	(8.30)	3.64	(17.95)	(7.91)	(17.76)	(27.16)	(23.83)	(26.38)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PEN Penumbra, Inc.	$12.7B	78.4×	63.5×	+14.90% (above 0%: growing)	−24.79% (below 0%: shrinking)	+10.81% (above 0%: growing)	67.93%	10.52%	Compare
SNN Smith & Nephew SNATS, Inc.	$12.2B	35.4×	18.6×	+7.99% (above 0%: growing)	−14.23% (below 0%: shrinking)	+293.94% (above 0%: growing)	69.42%	0.00%	Compare
GMED Globus Medical, Inc.	$10.6B	19.3×	20.3×	+5.94% (above 0%: growing)	−25.33% (below 0%: shrinking)	+571.30% (above 0%: growing)	69.42%	23.10%	Compare
BIO.B Bio-Rad Laboratories, Inc.	$10.3B	43.7×	—	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
GKOS Glaukos Corporation	$9.8B	— (loss-making)	— (loss-making)	+49.54% (above 0%: growing)	n/m	+211.83% (above 0%: growing)	81.67%	(9.30%)
BIO Bio-Rad Laboratories, Inc.	$9.8B	42.5×	35.4×	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
PODD Insulet Corporation	$9.6B	26.4×	24.7×	+23.51% (above 0%: growing)	+328.13% (above 0%: growing)	−70.51% (below 0%: shrinking)	70.18%	16.18%	Compare
BRKR Bruker Corporation	$8.6B	— (loss-making)	55.7×	+5.15% (above 0%: growing)	n/m	+28.63% (above 0%: growing)	49.61%	(7.79%)	Compare
HAE Haemonetics Corporation	$5.5B	57.7×	18.0×	+5.60% (above 0%: growing)	+2.86% (above 0%: growing)	+220.38% (above 0%: growing)	59.76%	16.93%	Compare
Median of peers	$10.0B	42.5×	24.7×	+5.77%	+2.86%	+19.72%	63.85%	11.15%

All 149 Medical Devices stocks →

Glaukos Corporation (GKOS) key facts

Strength: Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
Glaukos Corporation (GKOS) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, GKOS traded at $164.84, a market capitalization of $9.8 billion.
Return on equity was −26.4% and debt-to-equity 0.10.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 15.20 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.